- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Aflibercept Injection
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- PCV, Polypoidal Choroidal Vasculopathy
- Interventions
- high-dose ranibizumab, ranibizumab
- Drug
- Lead sponsor
- Hawaii Pacific Health
- Other
- Eligibility
- 25 Years to 95 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Honolulu, Hawaii • ‘Aiea, Hawaii
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab intravitreal injection
- Drug
- Lead sponsor
- Hawaii Pacific Health
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • ‘Aiea, Hawaii
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Neovascular Polypoidal Choroidal Vasculopathy
- Interventions
- Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
- Drug · Procedure
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Pigment Epithelial Detachment
- Interventions
- iSONEP (sonepcizumab/LT1009)
- Drug
- Lead sponsor
- Lpath, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more
- Conditions
- Idiopathic Polypoidal Choroidal Vasculopathy
- Interventions
- Zimura, Eylea
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- ‘Aiea, Hawaii
- Conditions
- Neovascular (Wet) AMD
- Interventions
- ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
- Drug
- Lead sponsor
- Avirmax Biopharma Inc
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more
- Conditions
- Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia, Central Serous Chorioretinopathy
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 7 Years to 100 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab 0.5 or 0.3 mg/0.05 cc
- Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Idiopathic Polypoidal Choroidal Vasculopathy
- Interventions
- Avacincaptad Pegol
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab 2.0mg
- Drug
- Lead sponsor
- Retina Consultants of Hawaii
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • ‘Aiea, Hawaii
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- fosbretabulin, Saline
- Drug
- Lead sponsor
- Mateon Therapeutics
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
- Interventions
- ranibizumab injection (0.5 mg)
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- Intravitreal aflibercept injection 2.0mg
- Drug
- Lead sponsor
- Gregg T. Kokame, MD
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- ‘Aiea, Hawaii